Revenue Breakdown
Composition ()
No data
Revenue Streams
Revvity Inc (RVTY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics, accounting for 54.7% of total sales, equivalent to $378.05M. Other significant revenue streams include Life sciences and Revenue purchase accounting adjustments. Understanding this composition is critical for investors evaluating how RVTY navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Revvity Inc maintains a gross margin of 53.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.05%, while the net margin is 6.76%. These profitability ratios, combined with a Return on Equity (ROE) of 3.04%, provide a clear picture of how effectively RVTY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RVTY competes directly with industry leaders such as GMED and PEN. With a market capitalization of $12.25B, it holds a significant position in the sector. When comparing efficiency, RVTY's gross margin of 53.60% stands against GMED's 63.28% and PEN's 67.78%. Such benchmarking helps identify whether Revvity Inc is trading at a premium or discount relative to its financial performance.
